A filing for ozanimod was initially rejected by the US regulator in February 2017.
News
Phase III results move Aimmune’s peanut allergy drug closer to EU market
Aimmune to file peanut allergy drug in Europe based on Phase III data showing an improvement in peanut tolerance.
Cancer immunotherapy alliance formed by CR UK, Lifearc and Ono Pharma Form
Cancer Research UK, LifeArc and Ono Pharmaceutical have formed a multi-million-pound drug discovery alliance.
Novartis’ MS drug gets FDA approval
The FDA has approved Novartis’ multiple sclerosis drug, Mayzent.
NICE recommendation for Steglatro in type II diabetes
MSD’s SGLT-2 inhibitor Steglatro will be available for some patients with type II diabetes on the NHS in England and Wales.
Sanofi plans to ‘airlift’ flu vaccine into UK in no-deal event
Sanofi has said that it could potentially airlift its flu vaccine into the UK in the event of a no-deal Brexit.
EU approves AZ’ Forxiga for type I diabetes
The drug is the first oral medicine approved in Europe as an adjunct to insulin for adults with type I diabetes.
Motif Bio raises £2.7 million via share placing
Motif Bio has announced that it has raised £2.7 million from a share placing, to provide additional working capital.
Tiziana submits IND for Foralumab oral formulation in NASH
Tiziana has submitted an Investigational New Drug application for an oral formulation of Foralumab.
Eisai, Biogen move Alzheimer’s treatment into Phase III
Eisai and Biogen’s BAN2401 is to be put into Phase III trial for patients with early Alzheimer’s disease.
Thermo Fisher buys Brammer Bio for $1.7bn
Thermo Fisher is set to acquire Brammer Bio for approximately $1.7 billion.
Rituximab found to extend progression-free survival in indolent lymphoma
New trial results have been published showing that a combination of Celgene’s Revlimid and Roche’s rituximab significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placebo.
Communications Team of the Year strengthens its steering panel for the 2019 competition
PharmaTimes are delighted to announce the formation of a dedicated executive steering group (ESG) for 2019. Due to the continued success and expansion of the communications competition, we are delighted to have been able to bring together such an exceptional team to help drive the competition forward.
Bayer to team up with patient compliance start-up Pilloxa
Swedish start-up Pilloxa has initiated a partnership with Bayer AB for an innovative smart pillbox.
UK Biotech still going strong at the start of 2019
The UK Biotech industry is showing a strong outlook at the start of 2019, despite the uncertainties of Brexit.
